Cargando…
Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B
BACKGROUND: Immunotherapeutic approaches designed to augment T and B cell mediated killing of tumor cells has met with clinical success in recent years suggesting tremendous potential for treatment in a broad spectrum of tumor types. After complex recognition of target cells by T and B cells, delive...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668111/ https://www.ncbi.nlm.nih.gov/pubmed/31362764 http://dx.doi.org/10.1186/s13046-019-1333-6 |